Successful Treatment of Granuloma Annulare with Certolizumab
Main Article Content
Keywords
granuloma annulare, certolizumab, treatment
Abstract
Generalized granuloma annulare (GA) is a subtype of GA that consists of widespread annular papules and plaques varying in size. There are no randomized trials of treatment for GA, however topical treatment, phototherapy, and various systemic therapies, have been reported to be effective. We report the first case of generalized GA that is successfully treated with certolizumab pegol.
References
2.American Academy of Dermatology Association. GRANULOMA ANNULARE : OVERVIEW 2019 [Available from: https://www.aad.org/public/diseases/rashes/granuloma-annulare.
3.National Center for Advancing Translational Sciences. Granuloma Annulare 2019 [updated August 02, 2018. Available from: https://rarediseases.info.nih.gov/diseases/6546/granuloma-annulare.
4.Schmieder SJ, Schmieder GJ. Granuloma Annulare. StatPearls. Treasure Island (FL)2019.
5.Goel N, Stephens S. Certolizumab Pegol. MAbs. 2010;2(2):137-47.
6. Chen A, Truong AK, Worswick S. The role of biologics in the treatment of chronic granuloma annulare. Int J Dermatol. 2019;58(5):622-26
7. Bürgler C, Vinay K, Häfliger S, Klötgen HW, Yawalkar N. Infliximab reduces activated myeloid dendritic cells, different macrophage subsets and CXCR3‐positive cells in granuloma annulare. 2019; J Dermatol(epub).
8. Min MS, Lebwohl M. Treatment of recalcitrant granuloma annulare (GA) with adalimumab: a single‐center, observational study. J Am Acad Dermatol. 2016 Jan;74(1):127-33.
9.Cessak G, Kuzawinska O, Burda A, Lis K, Wojnar M, Mirowska-Guzel D, et al. TNF inhibitors - Mechanisms of action, approved and off-label indications. Pharmacol Rep. 2014;66(5):836-44.
10.Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2011;4(6):375-89.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.